| 國立成功大學 |
2012-05-20 |
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).
|
Yau, TC (Yau, Thomas Cheung); Sukeepaisarnjaroen, W (Sukeepaisarnjaroen, Wattana); Chao, Y (Chao, Yee); Yen, CJ (Yen, Chia-Jui); Lausoontornsiri, W (Lausoontornsiri, Wirote); Chen, PJ (Chen, Pei-Jer); Sanpajit, T (Sanpajit, Theeranun); Lencioni, R (Lencioni, Riccardo); Camp, AC (Camp, Aaron C.); Cox, DS (Cox, Donna S.); Kallender, H (Kallender, Howard); Ottesen, LH (Ottesen, Lone Harild); Poon, RTP (Poon, Ronnie Tung-Ping) |
